A detailed history of Baker Bros. Advisors LP transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 683,588 shares of CERE stock, worth $0. This represents 0.37% of its overall portfolio holdings.

Number of Shares
683,588
Previous 1,600,000 57.28%
Holding current value
$0
Previous $67.6 Million 58.67%
% of portfolio
0.37%
Previous 0.86%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.96 - $42.75 $35.7 Million - $39.2 Million
-916,412 Reduced 57.28%
683,588 $28 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $32.4 Million - $67.9 Million
1,600,000 New
1,600,000 $67.8 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.